The Plasma Levels of PAl-1, TGF-β and TNF-αin Pleural Effusion before and after Intrapleural Injection of Kanglaite Combined with Cisplatin / 天津医药

ABSTRACT

Objective: To detect the levels of plasminogen activator inhibitor-I (PAI-1), transforming growth factor-β (TGF-β)and tumor necrosis factor-α (TNF-α) in the pleural fluid before and after intrapleural injection of Kanglaite combined with Cisplatin, and the mechanisms thereof. Methods: Patients were randomly divided into three groups, the Kanglaite combined with Cisplatin group (combination treatment group), Kangkaite group and Cisplatin group. The levels of PAl-1, TGF-β and TNF-α were determined by ELISA in pleural effusion 24 h and 48 h before and after intrapleural injection of medicine. Results: The levels of PAI-1, TGF-βand TNF-αawere higher 24 h and 48 h after treatment compared with those of pre-treatment in three groups (P＜0.05). There were no statistical significances in levels of PAI-1 and TGF-β24 h after injection medicine in three groups. But the level of TNF-α was higher in the combination treatment group than that in Kangkaite and Cisplatin groups(P＜0.05). After injection medicine 48 h, the levels of PAl-I, GF-β and TNF-α were higher in the combination treatment group than those in Kangkaite group (P＜0.05). Conclusion: The treatment of Kanglaite combined with Cisplatin activates PAI-1, TGF-β and TNF-αcytokines and causes inflammatory, suppresses fibrinolytic activity. These cytokines promote fibrin and induce pleural adhesion.